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Background: Aim of this study was to evaluate whether the A736V TMPRSS6 polymorphism, a major genetic
determinant of iron metabolism in healthy subjects, influences serum levels of hepcidin, the hormone regulating
iron metabolism, and erythropoiesis in chronic hemodialysis (CHD).
Methods: To this end, we considered 199 CHD patients from Northern Italy (157 with hepcidin evaluation), and 188
healthy controls without iron deficiency, matched for age and gender. Genetic polymorphisms were evaluated by
allele specific polymerase chain reaction assays, and hepcidin quantified by mass spectrometry.
Results: Serum hepcidin levels were not different between the whole CHD population and controls (median 7.1,
interquartile range (IQR) 0.55-17.1 vs. 7.4, 4.5-17.9 nM, respectively), but were higher in the CHD subgroup after
exclusion of subjects with relative iron deficiency (p = 0.04). In CHD patients, the A736V TMPRSS6 polymorphism
influenced serum hepcidin levels in individuals positive for mutations in the HFE gene of hereditary
hemochromatosis (p < 0.0001). In particular, the TMPRSS6 736 V variant was associated with higher hepcidin levels
(p = 0.017). At multivariate analysis, HFE and A736V TMPRSS6 genotypes predicted serum hepcidin independently of
ferritin and C reactive protein (p = 0.048). In patients without acute inflammation and overt iron deficiency (C
reactive protein <1 mg/dl and ferritin >30 ng/ml; n = 86), hepcidin was associated with lower mean corpuscular
volume (p = 0.002), suggesting that it contributed to iron-restricted erythropoiesis. In line with previous results, in
patients without acute inflammation and severe iron deficiency the “high hepcidin” 736 V TMPRSS6 variant was
associated with higher erythropoietin maintenance dose (p = 0.016), independently of subclinical inflammation
(p = 0.02).
Conclusions: The A736V TMPRSS6 genotype influences hepcidin levels, erythropoiesis, and anemia management in
CHD patients. Evaluation of the effect of TMPRSS6 genotype on clinical outcomes in prospective studies in CHD
may be useful to predict the outcomes of hepcidin manipulation, and to guide treatment personalization by
optimizing anemia management.
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Patients with end stage renal disease (ESRD) undergoing
chronic hemodialysis (CHD) are commonly affected by
anemia, which is related to erythropoietin (Epo) deficiency,
blood losses, and chronic inflammation [1]. Treatment is
based on erythropoiesis stimulating agents in association
with intravenous (i.v.) iron formulations, but is of often dif-
ficult to achieve and maintain the desired hemoglobin (Hb)
levels without incurring in side effects [2,3].
ESRD is characterized by major alterations in iron me-
tabolism including low transferrin saturation (TS),
resulting in reduced iron availability for the erythroblasts,
and hyperferritinemia [2,4]. Upregulation of serum levels
of hepcidin, the hepatic hormone regulating systemic iron
metabolism, has been proposed to explain the alterations
of iron metabolism of CHD patients and the resistance to
anemia treatment [5,6]. Increased serum levels of hepcidin
have indeed been reported in ESRD and CHD [2,5,7-11].
In response to increased iron stores, hepcidin inhibits
intestinal iron absorption and iron recycling from
monocytes by binding and inactivating the iron exporter
Ferroportin-1. The consequent inhibition of iron export
from duodenocytes and macrophages results in decreased
TS, and increases serum ferritin as a result of iron entrap-
ment into macrophages. Increased hepcidin in ESRD may
result from reduced glomerular filtration, subclinical in-
flammation, as hepcidin is an acute phase reactant, and
increased iron stores due to chronic supplementation. On
the other hand, hepcidin is downregulated by anemia,
hypoxia, and erythropoietin [12].
The upregulation of hepcidin transcription in response
to iron is mediated by a mechanism depending on the
interaction of various proteins including the heredi-
tary hemochromatosis protein HFE, and matriptase-2
(TMPRSS6). We previously reported that in CHD
patients common HFE mutations that alter hepatic iron
sensing [13] were associated with lower hepcidin levels
relatively to iron stores [6,14], achievement of target Hb
levels for lower doses of iron, and with reduced mortality
due to sepsis and cardiovascular disease, previously linked
to more intense iron supplementation [15-18]. These ini-
tial results are in line with the hypothesis that inhibition
of hepcidin in CHD may improve anemia control, and
even survival in CHD patients [2,3,19,20].
The TMPRSS6 gene encodes for matriptase-2, a
membrane-bound protease that decreases hepcidin tran-
scription by cleaving hemojuvelin. Rare loss-of-function
germline mutations of TMPRSS6 cause iron-refractory
iron-deficiency anemia related to extremely high hepcidin
levels, whereas the common rs855791 polymorphisms
resulting in the p.A736V substitution is a major determin-
ant of iron status in healthy subjects. Indeed, in the gen-
eral population the p.736 V allele (henceforth 736 V) has
been associated with lower serum iron, higher hepcidin[20,21], and decreased Hb [22-24], due to a less efficient
inhibition of hepcidin transcription [21]. Furthermore, the
p.A736V polymorphism has been shown to influence iron
overload in hereditary hemochromatosis and nonalcoholic
fatty liver disease [25,26]. However, it is not known
whether the A736V variant influences iron metabolism
during chronic inflammation and renal failure.
In the hypothesis that increased hepcidin is involved
in the deregulation of iron metabolism and the anemia
of CHD, the aim of this study were to evaluate whether
the TMPRSS6 A736V polymorphism influences hepcidin
levels and erythropoiesis parameters in CHD patients.
Methods
Subjects
We considered 199 CHD patients treated at the
Fondazione IRCCS Ca’ Granda Ospedale Maggiore
Policlinico from June 2006 to June 2011 [14]. Patients were
dialyzed with synthetic biocompatible membranes and bi-
carbonate dialysate thrice in week (t.i.w.), and given i.v. re-
combinant human Epo (EprexW) t.i.w., at a dose aimed to
maintain hemoglobin (Hb) between 10.5 and 12 g/dl. Iron
was administered i.v. as Fe3+-gluconate (FerlixitW) when TS
was less than 30% or ferritin <200 ng/ml, and suspended
when ferritin was above 500 ng/ml [27]. Iron infusion was
started once weekly and titrated according to requirements.
Baseline venous blood samples for complete blood
count, iron parameters, and markers of inflammation
(tested by standard methods) were collected in the
morning before hemodialysis (the first weekly session) at
standardized times after the last administration of ther-
apies potentially altering iron status and hepcidin re-
lease: one week after the last dose of i.v. iron, and 3 days
after the last dose of Epo (all these conditions were con-
temporarily satisfied for all patients). Aliquots of serum
samples for hepcidin-25 and hepcidin-20 measurement,
which were stored at −80°C until the analysis, were
available in a subset of 157 and 99 patients, respect-
ively [6]. Transferrin (TF) levels were only available
from 2007, so that this variable could not be included
in multivariate analyses.
We further selected a subgroup of 86 patients without
inflammation or severe iron deficiency at baseline evalu-
ation, arbitrarily defined on the basis of C reactive protein
(CRP) levels <1 mg/dl and serum ferritin concentra-
tion >30 ng/ml, to avoid the confounding effect of acute
inflammation and severe iron deficiency.
As reference population for hepcidin levels and for the
prevalence of the genetic variants under study, we ran-
domly selected 188 unrelated controls from the database of
Val Borbera study [20]. Controls were unrelated subjects,
with normal Hb (12–16 g/dl in females, 14–18 g/dl in
males), ferritin (30–200 ng/ml in females, 40–300 ng/ml in
males), and TS (16-45%), absence of homozygosity for the
Table 2 C282Y and H63D HFE and A736V TMPRSS6
genotypes of 183 CHD patients and 188 healthy controls
from the Val Borbera study (p = ns)
All patients Controls
HFE C282Y and H63D* N = 199 N = 188
wt/wt 139 (69.0) 112 (59.6)
H63D/wt 46 (23.0) 54 (28.7)
H63D/H63D 5 (2.5) 8 (4.3)
C282Y/wt 8 (4.0) 12 (6.4)
C282Y/H63D 3 (1.5) 2 (1.0)
TMPRSS6 A736V N = 183 N = 188
A/A 61 (33.3) 60 (31.9)
A/V 75 (41.0) 93 (49.5)
V/V 47 (25.7) 35 (18.6)
Table 1 Demographic, and clinical features of 199 consecutive CHD patients from Northern Italy with available
evaluation of C282Y and H63D HFE genotype (183 with A736V TMPRSS6 evaluation) and 188 healthy controls
All patients Ferritin >30 ng/ml and CRP <1 mg/dl Controls
N= 199 86 188
Gender F 79 (40) 40 (47) 82 (44)
Age years 64.3±14 c 63.8±14 60.0±17
BMI Kg/m2 22.5±5 c 21.9±4 c 26.2±4.2
Dialysis duration months 34 {13–82} 37 {16–87} -
Kt/V 1.3±0.2 1.3±0.2 -
Creatinine mg/dl 9.9±2.5 c 10.0±3 c 0.8±0.2
Active smoke 47 (24) 17 (20) 23 (16)
Albumin g/100 ml 3.7±0.5 3.8±0.4 -
CRP mg/dl 0.83 {0.4-2.5} c 0.40 {0.3-0.6} c 0.1 {0–0.2}
Hb g/dl 10.8±1.2 c 10.9±1.1 c 14.7±1.1
MCV fl 96±8 c 96±8 c 92±4
Serum iron μg/dl 55±23 c 58±19 c 98±25
Transferrin mg/dl 190±37 c 182±32 c 240±34
TS% 24.7±10 c 26.5±10 c 29.0±7
Ferritin ng/ml 265 {155–411} c 280 {204–445} c 84 {55–128}
Epo IU/Kg/week 100 {59–180} 106 {69–179} 0
Fe i.v. mg/month 94 {0–185} 93 {0–142} 0
Hepcidin-20 a nM 0.55 {0.55-5.3} c 1.39 {0.55-5.8} 0.87 {0.55-3.35}
Hepcidin-20 detectable 44 (45) 23 (51) 104 (55)
Hepcidin-25 b nM 7.1 {0.55-17.1} 6.8 {0.55-17.6} 7.4 {4.5-11.9}
Hepcidin-25 / ferritin b 0.024 c 0.021 c 0.080
{0.007-0.067} {0.005-0.051} {0.046-0.14}
():% values, {}: interquartile range, CRP: C reactive protein, Hb: hemoglobin, MCV: mean corpuscular volume, TS: transferrin saturation, Epo: erythropoietin,
IU: international units, i.v.: intravenous, wt: wild-type, available in 99 CHD patients (45 with ferritin >30 ng/ml and CRP <1 mg/dl) b available in 157 CHD patients
(57 with ferritin >30 ng/ml and CRP <1 mg/dl); c p < 0.05 vs. healthy controls.
Pelusi et al. BMC Nephrology 2013, 14:48 Page 3 of 9
http://www.biomedcentral.com/1471-2369/14/48C282Y HFE mutation, and normal kidney function
(estimated glomerular filtration rate according to simplified
MDRD >60 ml/min), matched for age (± 5 years) and
sex with CHD patients (for 11 patients, no match could
be found).
Clinical, genetic and demographic features of subjects
included in the study are shown in Table 1. Each patient
gave written informed consent. The study was conducted
according to the principles contained in the Declaration of
Helsinki. The protocol was approved by the Institutional
Review Board of the Fondazione IRCCS Ca’ Granda hos-
pital of Milan.
Genetic analysis and serum hepcidin assay
DNA was extracted from peripheral blood by the phenol-
chloroform method. HFE genotype (C282Y and H63D
variants) and the TMPRSS6 rs855791 C > T polymorph-
ism, (p.A736V variant) were assessed by sequence allele
specific PCR as previously described [25,28]. Random
samples were confirmed by direct sequencing. Quality
controls were performed to verify the reproducibility
Table 4 Clinical variables associated with hepcidin-25
levels at Spearman’s rho test (univariate analysis) in 86
CHD patients from Northern Italy with ferritin levels >
30 ng/ml and CRP < 1 mg/dl (the characteristics of this
subset of patients are reported in Table 1 and related
results; associated variables are shown for p < 0.1)
R p
Ferritin ng/ml +0.38 <0.0001
MCV fl −0.47 0.002
Transferrin mg/dl −0.23 0.012
TS% +0.23 0.069
CRP mg/dl +0.21 0.095
MCV: mean corpuscular volume; TS: transferrin saturation; CRP: C reactive protein.
Table 3 Clinical and genetic variables associated with hepcidin-25 levels at Spearman’s rho test (univariate analysis)
and multivariate analysis in CHD patients from Northern Italy
Univariate GLM model 1 GLM model 2
R P Estimate p Estimate p
Ferritin ng/ml +0.30 0.0001 0.27 0.004 0.27 0.005
CRP mg/dl +0.29 0.0004 0.29 0.01 0.28 0.010
Transferrin mg/dl −0.20 0.03 - - - -
Epo IU/Kg/week +0.16 0.06 0.18 0.94 - -
HDL mg/dl −0.20 0.06 - - - -
Albumin g/l −0.15 0.06 - - - -
TMPRSS6 A/A HFE muts + vs. other genotypes −0.19 0.02 - - −0.17 0.048
Generalized linear model (GLM) 1 included clinical variables correlated with hepcidin-25 at univariate analysis (reported for p < 0.1), which were available in the
majority of patients, i.e. ferritin, CRP levels, and Epo dose (157 subjects included). The second model considered the major clinical independent determinants of
hepcidin, plus the genetic factors analyzed (143 subjects included).
CRP: C reactive protein; Epo: erythropoietin, IU: international units, HDL: high density lipoprotein cholesterol; HFE muts +: positive for HFE mutations;
GLM: generalized linear model.
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100% of subjects analyzed. For 13 patients (6.5%) only
HFE genotype was available from a previous study,
due to the lack of possibility to get the consent for new
genetic studies.
For hepcidin measurement, we used a protocol based
on SELDI-TOF mass spectrometry and copper-loaded
immobilized metal-affinity capture ProteinChip arrays
(IMAC30-Cu2+) [29], extensively validated in previous
studies [13,20,21]. Concentrations of serum hepcidin-25
and hepcidin-20 were expressed as nM.
Statistical analysis
Results are expressed as means ± SD for normally
distributed variables and as median {interquartile range}
for non-normally distributed variables. Variables were
correlated by Spearman’s rho test, and data compared
between groups by t-test or Wilcoxon test, according to
data distribution. Frequencies were compared by Chi-
square test. We also evaluated the hepcidin-25/ferritin
ratio (H/F), an established marker of adequacy of
hepcidin response to iron stores. Independent predictors
of serum hepcidin-25 and Epo requirements were
evaluated by multivariate analysis (generalized linear
model, GLM) including the variables identified as signifi-
cantly associated with hepcidin at univariate analysis and
available for all subjects, as specified in the result sec-
tion. Log transformations were applied to normalize
skewed variables before multivariate analysis. Results
were considered significant when p was lower than 0.05
(two-tailed).
Results
Frequency distribution of HFE and TMPRSS6 variants and
hepcidin levels in patients and controls
The frequency distribution of the C282Y and H63D HFE
variants and A736V of the TMPRSS6 variant did notviolate Hardy-Weinberg equilibrium in both patients
and controls (p > 0.1; Table 2), and was not significantly
different between the two groups (p = ns). Serum
hepcidin-25 levels were not significantly different be-
tween the whole group of CHD patients and controls
(Table 1), whereas H/F ratio was lower in patients
(Table 1). One hundred-four (52.3%) of CHD patients
were classified as “iron-deficient” on the basis of
guidelines for iron treatment in CHD, which takes
into account the effect of inflammation on ferritin
(ferritin <200 ng/ml and TS <30%) [27]. After the exclu-
sion of these subjects, hepcidin-25 was higher in patients
(9.31 {3.11-22.4} nM) than in controls (p = 0.04).
Clinical determinants of hepcidin in CHD patients
Clinical variables associated with hepcidin-25 levels in
CHD patients are shown in Table 3. Hepcidin-25 was
correlated with ferritin and CRP levels, and negatively
associated with TF. In patients without severe iron defi-
ciency and with normal CRP levels (Table 4), hepcidin-
25 was correlated with ferritin, and inversely correlated
with TF and mean corpuscular volume (MCV) values.
Table 5 Clinical variables associated with hepcidin-20
levels at at Spearman’s rho test (univariate analysis) and
multivariate generalized linear model (GLM) in 99 CHD
patients from Northern Italy (reported for p < 0.1 for
clinical variable)
Univariate GLM
R P Estimate p
Hepcidin-25 nM +0.60 <0.0001 +0.63 <0.0001
Active smoke −0.25 <0.0001 −0.27 0.0016
Transferrin mg/dl −0.23 0.032 - -
TS% +0.21 0.039 +0.13 0.22
TMPRSS6 A/A HFE muts + vs.
other genotypes
−0.18 0.12 +0.13 0.99
TS: transferrin saturation; HFE muts +: positive for HFE mutations;
GLM: generalized linear model.
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allows also the quantification of hepcidin-20, an amino-
terminal truncated isoform, which is postulated to repre-
sent a degradation product of hepcidin-25 with no activity
on iron metabolism, but possibly involved in antimicrobial
response. Regarding the truncated hepcidin isoform
(hepcidin-20) [30], the absolute levels were slightly lower
in the whole CHD group than in controls, but these data
were available in a limited subgroup of patients, and the
prevalence of detectable hepcidin-20 levels was the same
as in controls. On the other hand, absolute hepcidin-20
levels were slightly higher in the CHD subgroup of
patients without functional iron deficiency (Table 1), while
the difference did not reach statistical significance. Be-
cause of the small subgroups that could be analyzed, it is
possible that these nominal differences represent false
positive results, and no definite conclusion can be drawn.
Variables associated with hepcidin-20 levels are shown in
Table 5. The major determinant of hepcidin-20 wasFigure 1 Effect of HFE C282Y and H63D genotype status (wild-type, h
hepcidin-25 levels (panel A), and hepcidin-25 / ferritin ratio (panel B)hepcidin-25, but active smoking was also independently
associated with lower hepcidin-20. In control subjects,
serum hepcidin-20 levels were not significantly lower in
active smokers vs. non-smokers and previous smokers
(median 0, IQR {2.99-6.38}, vs. 1.67 {3.68-6.59} nM, re-
spectively; p = 0.17), even after correction for hepcidin-25
(p = 0.08).
Effect of TMPRSS6 and HFE variants on hepcidin, iron,
and erythropoiesis
The effect of HFE genotype (wild-type, heterozygosity
for C282Y and H63D mutations, and other genotypes)
on hepcidin-25 in CHD patients is shown in Figure 1A.
Hepcidin-25 was lower in patients with HFE mutations
than in those without (p = 0.01), in particular in those
carrying the C282Y mutation or homozygous for the
H63D mutation (p = 0.0004). The effect of HFE genotype
on the H/F ratio is shown in Figure 1B. The H/F ratio
was lower in patients with HFE mutations than in
those without (p = 0.04). Therefore, we grouped to-
gether patients with any HFE mutation in further
analyses, in order to better characterize the effect of
TMPRSS6 genotype.
The combined HFE (presence or absence of HFE
mutations) and TMPRSS6 A736V genotypes influenced
serum hepcidin-25 levels (p < 0.0001; Figure 2A). In line
with the hypothesized negative effect of HFE mutations
and of the 736A allele on hepcidin transcription, patients
negative for HFE mutations had higher hepcidin-25 levels
than patients with 736A/A and positive for HFE mutations
(p < 0.05). Furthermore, in patients with HFE mutations,
those with the 736 V/V genotype had higher hepcidin-25
than those with the 736A/A genotype (p = 0.017). Similar
results were obtained for the H/F ratio in CHD patients, i.e.
the 736 V/V genotype was associated with significantlyeterozygosity for the H63D mutation, other genotypes) on
in 155 CHD patients from Northern Italy.
Table 6 Association of TMPRSS6 A736V polymorphism
(736 V allele, additive model) with iron and
erythropoietic parameters at Spearman’s rho test
(univariate analysis) in 86 CHD patients from Northern
Italy with ferritin > 30 ng/ml and CRP < 1 mg/dl (the
characteristics of this subset of patients are reported in
Table 1 and related results; associated variables are
shown for p < 0.1)
R p
Serum iron μg/ml −0.26 0.077
CRP mg/dl +0.22 0.061
MCV fl −0.28 0.061
Epo IU/Kg/week +0.28 0.027
CRP: C reactive protein; MCV: mean corpuscular volume; Epo: erythropoietin;
IU: international units.
Figure 2 Combined effect of HFE C282Y and H63D and TMPRSS6 rs855791 (A736V) polymorphisms on hepcidin-25 levels in 143 (panel A),
and on hepcidin-20 in 99 (panel B) CHD patients from Northern Italy. # p < 0.05 vs. TMPRSS6 A/A and HFE mutations present.
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not in those without HFE mutations (not shown).
At multivariate analysis (Table 3), the HFE positive 736A/
A genetic status was associated with lower hepcidin-25
levels independently of ferritin and CRP levels (p = 0.048).
Patients negative for HFE mutations had higher
hepcidin-20 levels than patients with 736A/A plus HFE
mutations (Figure 2B). At multivariate analysis (Table 5),
the effect of genetic factors on hepcidin-20 levels was
not independent of hepcidin-25 levels.
Besides with hepcidin-25 values, as in the general popu-
lation [20] the presence of HFE mutations was associated
with lower TF levels (p = 0.03), and with a lower dose of
iron supplementation to achieve the Hb target (p = 0.03).
TMPRSS6 A736V polymorphism was not associated
with Hb levels and iron parameters in the overall CHD
cohort. In order to avoid the confounding effect of acute
inflammation and severe iron deficiency, we analyzed
whether the TMPRSS6 A736V polymorphism influenced
iron parameters and erythropoiesis in patients with CRP
< 1 mg/dl and ferritin > 30 ng/ml. Results are presented
in Table 6. In this subset of patients, the number of
“high hepcidin” 736 V alleles was correlated with higher
Epo requirement to control anemia (p = 0.027). In line
with the negative effect of increased hepcidin on iron
availability and erythropoiesis, there was also a trend for
an association between the 736 V allele and lower iron
and MCV values. At multivariate analysis adjusted for
CRP levels, the number of 736 V TMPRSS6 alleles
carried by CHD patients was associated with the weight-
adjusted Epo dosage required to achieve the target Hb
levels (p = 0.02, estimate coefficient 45, 95% c.i. 7–82).
Discussion
In CHD patients, it is usually difficult to control anemia
because of a complex derangement of iron metabolism,which is due to chronic inflammation, blood losses, and
concomitant Epo administration [2]. Increased serum
levels of hepcidin, the hepatic hormone regulating iron
metabolism, have been suggested to contribute to the
functional iron deficiency that limit erythropoiesis in
CHD [2,3,31]. Differently from what reported in smaller
series of patients with unmatched controls, including
previous studies from our group [5-8,32,33], we found
that hepcidin-25 levels were not significantly increased in
the whole CHD population. Nevertheless, accordingly to
the previous reports [5-8,32,33], the major determinants
of hepcidin were serum ferritin and CRP levels. The fail-
ure to confirm a relative hyper-hepcidinemia in the overall
CHD cohort could be explained by a number of reasons:
i) the inclusion of a large and less selected CHD popula-
tion compared to previous studies, more closely reflecting
patients observed in clinical practice, including those re-
quiring high doses of Epo and with relative iron deficiency
(factors both known to reduce hepcidin), as suggested by
higher hepcidin levels in patients without functional iron
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cohort (as reflected by median serum ferritin levels of only
265 ng/ml, Table 1) because of a local policy aimed at
minimizing iron supplementation, due to long standing
interest in iron metabolism and the side effects of iron
overload; and iii) at variance with previous studies, e.g.
Zaritsky et al. [32], the meticulous matching of the
controls for age and gender, recently established as major
determinants of hepcidin-25 at population level [20,34], as
well as the systematic exclusion of even subclinical iron
deficiency in controls, which both contributed to a more
realistic comparison of hepcidin-25 levels than those made
until now. Accordingly with these considerations, how-
ever, when CHD patients with relative iron deficiency
were excluded from these analyses, hepcidin-25 was actu-
ally higher in CHD than in controls. Anyway, the com-
parison of hepcidin levels between CHD patients and
controls was not the main aim of the present study, which
was not therefore specifically designed to achieve this goal.
Our results in this sense need to be confirmed in similarly
large patient populations and matched controls.
Clearance of hepcidin by hemodialysis [29] may pos-
sibly compensate for increased production, and explain
the reduced H/F ratio in patients compared to controls.
Notwithstanding, in patients without severe iron defi-
ciency and active inflammation at the time of evaluation,
hepcidin was associated with lower MCV, i.e. with iron-
restricted erythropoiesis, suggesting that it negatively
influences iron availability to the erythron, and that it
represents a potential therapeutic target to improve
anemia management.
The specific aim of this study was to evaluate whether
the A736V TMPRSS6 polymorphism regulating hepcidin
transcription, a determinant of iron-restricted erythro-
poiesis in the general population [21,35], influences
hepcidin levels and erythropoiesis in CHD. To increase
the power of this analysis, patients were stratified for the
presence of loss-of-function HFE mutations, that we pre-
liminarily confirmed to influence hepcidin in this series [6].
The major finding was that the 736 V TMPRSS6 loss-of
-function variant appears to modulate the effect of HFE
mutations on hepcidin. Indeed, the A736V polymorphism
influenced serum hepcidin in patients positive for HFE
mutations. This suggests that the 736 V variant with defect-
ive proteolytic activity determining increased hepcidin tran-
scription [21] may abrogate the inhibitory effect of HFE
mutations on hepcidin. Thus, the A736V TMPRSS6 variant
appears as a modifier of the phenotypic expression of HFE
mutations in patients with CHD, who are characterized by
chronic subclinical inflammation.
Furthermore, in patients without overt iron deficiency
and acute inflammation, the 736 V variant was associated
with higher hepcidin levels and with higher requirement
of Epo for anemia management, thus suggesting that theeffect of TMPRSS6 genotype translates into clinically de-
tectable differences in erythropoiesis. Importantly, at
multivariate analysis the association between TMPRSS6
genotype and Epo maintenance dose was independent of
subclinical inflammation, as indicated by CRP levels.
These data are in line with the association between
TMPRSS6 736 V with hepcidin levels, and in turn with
the positive association of hepcidin with the Epo mainten-
ance dose in the same subgroup. Therefore, inhibition of
hepcidin might be helpful for a better control of anemia in
patients predisposed to high hepcidin release [19]. Evalu-
ation of the impact of HFE and TMPRSS6 genotype on
the survival of CHD patients after adequate follow-up
would be instrumental to fully define their clinical impact.
Conclusions
In conclusion, in CHD patients the A736V TMPRSS6
genotype influences hepcidin levels, and in the absence
of acute inflammation and severe iron deficiency, also
erythropoiesis and anemia management. Evaluation of
the effect of TMRPSS6 genotype on clinical outcomes in
prospective studies in CHD patients may be useful to
predict the outcomes of hepcidin manipulation, to de-
velop new approaches to optimize anemia management,
and to guide treatment personalization.
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